Last reviewed · How we verify
other injectable antidiabetic treatment regimens
other injectable antidiabetic treatment regimens is a Small molecule drug developed by Novo Nordisk A/S. It is currently in Phase 2 development.
At a glance
| Generic name | other injectable antidiabetic treatment regimens |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- other injectable antidiabetic treatment regimens CI brief — competitive landscape report
- other injectable antidiabetic treatment regimens updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about other injectable antidiabetic treatment regimens
What is other injectable antidiabetic treatment regimens?
other injectable antidiabetic treatment regimens is a Small molecule drug developed by Novo Nordisk A/S.
Who makes other injectable antidiabetic treatment regimens?
other injectable antidiabetic treatment regimens is developed by Novo Nordisk A/S (see full Novo Nordisk A/S pipeline at /company/novo-nordisk).
What development phase is other injectable antidiabetic treatment regimens in?
other injectable antidiabetic treatment regimens is in Phase 2.